TABLE 9.

Seroprotection rates per time point and study for the anti-HBs in-house assay versus the AUSAB RIA and EIA reference assays

Study	No. of subjects/groupa	Time pointb	% Seroprotection in:
			Vaccine group 1			Vaccine group 2			Vaccine group 3
			In-house assay	RIA	EIA	In-house assay	RIA	EIA	In-house assay	EIA
A	72	PI, mo 1	15.3	20.8		0.0	2.7
	72	PII, mo 2	80.6	81.9		23.6	26.4
	72	PII, mo 6	95.8	93.1		59.7	56.9
	72	PIII, mo 7	98.6	98.6		81.9	83.3
B	51	PI, mo 1	47.1	49.0		63.6	63.6
	51	PII, mo 2	60.8	60.8		81.8	81.8
	50	PII, mo 6	48.0	42.0		85.2	81.5
	47	PIII, mo 7	72.3	72.3		96.2	96.2
C	100	PI, mo 1	2.0	2.0		9.7	12.5
	72	PII, mo 2	80.6	68.1		68.1	69.4
	72	PII, mo 6	93.1	93.1		95.8	95.8
	72	PIII, mo 7	98.6	97.2		100.0	100.0
D	72	PIII, mo 7	97.2		95.8	97.2		97.2	97.2	97.2
E	134	PI/II, mo 2	53.0	40.3	41.8	90.4	86.8	86.8
	145	PII/III, mo 7	99.3	98.6	99.3	100.0	100.0	100.0
F	50	Pre	13.8	16.9		12.2	12.2
	50	PII, mo 6	98.0	98.0		96.0	96.0
	50	PII, mo 8	94.0	94.0		100.0	100.0
	50	PIII, mo 9	100.0	100.0		100.0	100.0
G	34	Pre, mo 1.5	52.9		49.0	59.6		68.4
	47	PIII, mo 7	100.0		100.0	95.9		95.0
	53	PIII, mo 15	96.6		96.6	93.0		96.0
	57	PIV, mo 6	100.0		100.0	98.3		98.3

^aIf the number between the two groups was different, the lowest number was taken.

^bPre, sample taken prior to vaccination; PI to PIV, postdose months 1 to 4, respectively; mo 1, mo 2, etc., study month 1, study month 2, etc.